Trial Profile
A phase II study to determine relapse-free interval after withdrawal of imatinib therapy in adult patients with chronic phase chronic myeloid leukaemia in stable complete molecular remission.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Sep 2020
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms TWISTER
- 06 Dec 2016 Results of this and other study (n=85) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 30 Aug 2011 New trial record